Advances in viral clearance

Process Scale Bioseparations for the Biopharmaceutical Industry

Volumn , Issue , 2006, Pages 449-462

  Brorson, Kurt ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59449110127     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (29)

1. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use; Docket No. 94D-0259; Food and Drug Administration: Rockville MD, 1997.
2. Guidance on Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin, Q5A; International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1998.
3. Brorson, K., Norling, L., Hamilton, E., Lute, S., Lee, K., Curtis, S., and Xu, Y., Current and future approaches to ensure the viral safety of biopharmaceuticals. Dev. Biol. (Basel), 2004, 118, 17-29.
4. Farshid, M., Taffs, R., Scott, D., Asher, D., and Brorson, K., The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Curr. Opin. Biotechnol., 2005, 16, 1-7.
5. Roberts, P., Virus safety of plasma products. Rev. Med. Virol., 1996, 6, 25-38.
6. Horowitz, B. and Ben-Hur, E., Efforts in minimizing risk of viral transmission through viral inactivation. Ann. Med., 2000, 32, 475-484.
7. Gilbert, J., Henske, P., and Singh, A., Rebuilding Big Pharma's Business Model; Windhover Information: November 2003.
8. PDA process validation task force: Process validation of protein manufacturing (TR42); PDA: Bethesda MD. PDA J. Pharm. Sci. Technol., 2005, 59, 5-9.
9. Curtis, S., Lee, K., Blank, G.S., Brorson, K., and Xu, Y., Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotechnol. Bioeng., 2003, 84, 179-186.
10. Chen, Q., Bracketed Matrix Evaluation of X-MuLV and SV40 Clearance by Anion Exchange Chromatography in Flow-Through Mode. Presented at BioProduction 2005, Amsterdam, October 25-27, 2005.
11. Brorson, K., Krejci, S., Lee, K., Hamilton, E., Stein, K., and Xu, Y., Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol. Bioeng., 2003, 82, 321-329.
12. Pharmaceutical Development Q8 (draft); International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 2004.
13. PDA virus filter task force: Virus Filtration (TR41); PDA: Bethesda MD, 2005.
14. Brorson, K., Sofer, G., Robertson, G., Lute, S., Martin, J., Aranha, H., Haque, M., Satoh, S., Yoshinari, K., Moroe, I., Morgan, M., Yamaguchi, F., Carter, J., Krishnan, M., Stefanyk, J., Etzel, M., Riorden, W., Korneyeva, M., Sundaram, S., Wilkommen, H., and Wojciechowski, P., Large pore size virus test method recommended by the PDA virus filter task force. PDA J. Pharm. Sci. Technol., 2005, 59, 177-186.
15. Brough, H., Antoniou, C., Carter, J., Jakubik, J., Xu, Y., and Lutz, H., Performance of a novel viresolve NFR virus filter. Biotechnol. Prog., 2002, 18, 782-795.
16. Bolton, G., Cabatingan, M., Rubino, M., Lute, S., Brorson, K., and Bailey, M., Normal flow virus filtration - detection and assessment of endpoint in Bioprocessing. Biotechnol. Appl. Biochem., 2005, 42, 133-142.
17. Lute, S., Aranha, H., Tremblay, D., Liang, D., Ackermann, H.W., Chu, B., Moineau, S., and Brorson, K., Characterization of coliphage PR772 and evaluation of its use for virus filter performance testing. Appl. Environ. Microbiol., 2004, 70, 4864-4871.
18. Biesert, L. and Suhartono, H., Solvent/detergent treatment of human plasma-a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang, 1998, 74, 207-212.
19. Horowitz, B., Lazo, A., Grossberg, H., Page, G., Lippin, A., and Swan, G., Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang, 1998, 74, 203-206.
20. Brorson, K., Brown, J., Hamilton, E., and Stein, K.E., Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J. Chromatogr. A, 2003, 989, 155-163.
21. Brorson, K., Swann, P.G., Lizzio, E., Maudru, T., Peden, K., and Stein, K.E., Use of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus levels in mAb cell-culture and downstream processing. Biotechnol. Prog., 2001, 17, 188-196.
22. Norling, L., Lute, S., Emery, R., Khuu, W., Voisard, M., Xu, Y., Chen, Q., Blank, G.S., and Brorson, K., Impact of multiple re-use of anion-exchange chromatography media on virus removal. J. Chromatogr. A, 2005, 1069, 79-89.
23. Specht, R., Han, B., Wickramasinghe, S.R., Carlson, J.O., Czermak, P., Wolf, A., and Reif, O.W., Densonucleosis virus purification by ion exchange membranes. Biotechnol. Bioeng., 2004, 88, 465-473.
24. Roberts, P. and Hope, A., Virus inactivation by high intensity broad spectrum pulsed light. J. Virol. Meth., 2003, 110, 61-65.
25. Akeprathumchai, S., Han, B., Wickramasinghe, S.R., Carlson, J.O., Czermak, P., and Preibeta, K., Murine leukemia virus clearance by flocculation and microfiltration. Biotechnol. Bioeng., 2004, 88, 880-889.
26. Kamei, D.T., King, J.A., Wang, D.I., and Blankschtein, D., Separating lysozyme from bacteriophage P22 in two-phase aqueous micellar systems. Biotechnol. Bioeng., 2002, 80, 233-236.
27. Xu, Y. and Brorson, K., An overview of quantitative PCR assays for biologicals: quality and safety evaluation. Dev. Biol. (Basel), 2003, 113, 89-98.
28. Valera, C.R., Chen, J.W., and Xu, Y., Application of multivirus spike approach for viral clearance evaluation. Biotechnol. Bioeng., 2003, 84, 714-722.
29. Brorson, K., Xu, Y., Swann, P.G., Hamilton, E., Mustafa, M., de Wit, C., Norling, L.A., and Stein, K.E., Evaluation of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus in mAb cell-culture. Biologicals, 2002, 30, 15-26.